Interleukin-1β plasma levels are associated with depression in temporal lobe epilepsy

Vieira, Érica Leandro Marciano; Oliveira, Guilherme Nogueira Mendes de; Lessa, João Marcelo K.; Gonçalves, Ana Paula; Sander, Josemir W.; Cendes, Fernando; Teixeira, Antônio Lúcio

doi:10.1016/j.yebeh.2015.09.035

Cited by 19 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, brain inflammation has been well established in patients with TLE and corroborated in various animal models of chronic epilepsy . Elevated blood levels of CRP, S100β, and IL‐6 have been observed in patients with epilepsy, whereas increased plasma levels of IL‐1β have been specifically connected with epilepsy‐associated depression . Similarly, increased levels of plasma IL‐1β, IL‐6, TNF‐α, CRP, and S100β protein have been detected in an animal TLE model .…”

Section: Potential Molecular Biomarkers Of Comorbiditiesmentioning

confidence: 83%

“…32 Elevated blood levels of CRP, S100b, and IL-6 have been observed in patients with epilepsy, [33][34][35] whereas increased plasma levels of IL-1b have been specifically connected with epilepsy-associated depression. 36 Similarly, increased levels of plasma IL-1b, IL-6, TNF-a, CRP, and S100b protein have been detected in an animal TLE model. 37,38 Although the latter studies did not directly connect inflammatory biomarkers with depressive impairments, the employed epilepsy model is consistently characterized by depressive behavior.…”

Section: Stress Hormone Axismentioning

confidence: 88%

See 1 more Smart Citation

WONOEP appraisal: Biomarkers of epilepsy‐associated comorbidities

et al. 2016

View full text Add to dashboard Cite

Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31-September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the "Janus Kinase/Signal Transducer and Activator of Transcription," "mammalian Target of Rapamycin," and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.

show abstract

Section: Potential Molecular Biomarkers Of Comorbiditiesmentioning

confidence: 83%

Section: Stress Hormone Axismentioning

confidence: 88%

WONOEP appraisal: Biomarkers of epilepsy‐associated comorbidities

et al. 2016

View full text Add to dashboard Cite

show abstract

“…IL‐1β functions as a seizure‐associated proinflammatory mediator, accumulated in the brain during epilepsy . Moreover, IL‐1β can function as a modulator in the hippocampus and is crucial for potentiation maintenance of long period, and plasma levels of IL‐1β might be correlated to depression in patients suffering from temporal lobe epilepsy . The activity of the IL‐1 system is dependent on the equilibrium between the agonist/antagonist ligands of IL‐1β and IL‐1Ra, and the imbalance in IL‐1β/IL‐1Ra ratio may stimulate the inflammatory responses of extra‐cerebral human diseases .…”

Section: Discussionmentioning

confidence: 99%

The roles of interleukin‐1 and RhoA signaling pathway in rat epilepsy model treated with low‐frequency electrical stimulation

Liu

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aims to explore the correlation between interleukin-1 (IL-1) and epilepsy in rats when treated with low-frequency electrical stimulation via the RhoA/ROCK signaling pathway. Twenty-four SD rats were elected for this study, among which six rats were assigned as the normal group. And 16 rat models with epilepsy were successfully established and assigned into the model group, the ES group and the ES + IL-8 group, with each group comprising of six rats. The seizure frequency and duration was recorded. Electroencephalogram (EEG) power was detected at α1, α2, β, θ, and δ. The mRNA expressions of IL-1β and IL-1R1 were detected using reverse transcription quantitative polymerase chain reaction (RT-qPCR), and the protein expressions of RhoA, ROCK I and ROCK II were detected by western blotting. In comparison with the model group, the seizure frequency duration, the power of δ, θ, α1, α2, and β, the mRNA and protein expressions of IL-1β and IL-1R1, the expressions of RhoA and ROCK I proteins, and the ratio of RhoA protein between membrane and cytosol decreased in the ES group, while the expression of ROCK II increased (all P < 0.05). There was no significant difference in these indexes between the ES + IL-8 group and the model group (all P > 0.05). These findings signified that IL-1 might inhibit the efficacy of low-frequency ES for epilepsy via the RhoA/ROCK signaling pathway, which may provide a theoretical basis for clinical treatment of epilepsy.

show abstract

“…In comparison, the IL-6 level in tears of healthy subjects is more than 100 pg/ml (59,61). The plasma concentration of IL-1β in healthy controls is about 2.5 pg/ml, while the IL-1β level in tears of healthy subjects is about 100 pg/ml (59,62). At the same time, in infectious inflammation, the levels of these cytokines in tears sometimes increase by more than 10 times (63).…”

Section: Cytokines Level and Immune Tolerancementioning

confidence: 94%

Immune Tolerance as the Physiologic Counterpart of Chronic Inflammation

Rogovskii

2020

Front. Immunol.

View full text Add to dashboard Cite

Interleukin-1β plasma levels are associated with depression in temporal lobe epilepsy

Cited by 19 publications

References 32 publications

WONOEP appraisal: Biomarkers of epilepsy‐associated comorbidities

WONOEP appraisal: Biomarkers of epilepsy‐associated comorbidities

The roles of interleukin‐1 and RhoA signaling pathway in rat epilepsy model treated with low‐frequency electrical stimulation

Immune Tolerance as the Physiologic Counterpart of Chronic Inflammation

Contact Info

Product

Resources

About